Pancreatic tumour imaging poses one of the greatest challenges in gastroenteropancreatic tumour diagnostics. Though much less common than adenocarcinomas, tumours deriving from pancreatic islets are the second most common group of pancreatic tumours. The manifestations and growth rate of neuroendocrine tumours (NETs) differ from adenocarcinomas; thus, these tumour types require different diagnostic and therapeutic approaches. With its high sensitivity and specificity, endoscopic ultrasound (EUS) seems to be indispensable in pancreatic NET diagnostics. A negative EUS practically excludes the presence of a pancreatic tumour, while in definitive tumour cases, EUS is helpful in tumour staging, and in determining its precise anatomical location. One especially important benefit of EUS is the option of performing a biopsy for subsequent cytological and histopathological examinations. The use of contrast and additional computerized image analysis increases the diagnostic accuracy of EUS. This article presents current views on the use of EUS in pancreatic tumour diagnostics, with a particular emphasis on diagnosing NETs.
INTRODUCTION
Pancreatic cancer is the most common and most dangerous gastrointestinal tumours. In Poland, its incidence has nearly doubled over the past 30 years. Experts from United European Gastroenterology (UEG) have confirmed that pancreatic cancer incidence has been on the rise in a number of European Union countries. It is estimated that in 2025 the number of deaths caused by pancreatic cancer will amount to 111.5 thousand in Europe, which is a 50% increase as compared with the year 2010. Pancreatic cancer will then become the third most common cause of death due to malignancy in Europe, following lung and colorectal cancers [1] .
PANCREATIC ADENOCARCINOMA
Standardized incidence ratios for pancreatic cancer in the Polish population are virtually tantamount to the mortality ratios in that case, amounting to 6.2 and 4.2/100 000/year for male and female patients, respectively [2] . Malignant pancreatic tumours include adenocarcinomas, neuroendocrine tumours, solid pseudopapillary tumours, stromal tumours, lymphomas and metastatic lesions. Amongst the above mentioned tumours, adenocarcinoma is the one with the poorest prognosis, with mean survival after the diagnosis of advanced or metastatic cancer totalling less than 6 months. 5-year survival is reached by just under 5% of patients diagnosis of pancreatic cancer appears to be a crucial factor that improves patient prognosis [7] .
PANCREATIC NEUROENDOCRINE TUMOURS
The second most common group of pancreatic neoplasms are islet cells tumours. They are much less common, though, accounting for only 1-5% of pancreatic cancers, with their incidence estimated as ca. 1 case per 100 thousand persons per year [8] [9] [10] [11] .
They are usually diagnosed in the patient's fourth and fifth decade of life, and are slightly more common in women than in men.
They may further be divided into functioning (70% of all cases) and non-functioning, hereditary and sporadic, malignant and benign ones [8] [9] [10] . 
ENDOSCOPIC ULTRASOUND IN THE DIAGNOSIS OF PANCREATIC TUMOURS

ENDOSCOPIC ULTRASOUND IN THE DIAGNOSIS OF PANCREATIC NETS
Neuroendocrine tumours may be revealed on EUS in different forms, including solid lesions, uniformly or non-uniformly (as a result of necrosis) hypoechogenic. Sometimes they take the form of encapsulated cystic lesions (ca. 10-20% of the cases), and much more rarely, they are manifested as normo-and hyperechogenic nodules [9, 10] . In Doppler ultrasound, an enhanced flow within the tumour is usually revealed, which is associated with a rich vasculature ( fig. 3 ).
What is important in the diagnosis of pancreatic NETs is a much higher resolution of the method as compared with the classical ultrasound assessment, and the possibility of acquiring images from the immediate vicinity of the pancreas, with no limitations related to the presence of intestinal gas. EUS is the most sensitive of the currently available imaging methods applied in the diagnostics of pancreatic focal lesions, as it is capable of detecting lesions as small as 1-2 mm in diameter. Sensitivity of the test for tumours located within the head and tail of the pancreas is 90-100%, whereas for those with peripheral location it is 75-80% [17] [18] [19] [20] . In the case in small insulinomas, EUS sensitivity reaches 94-100% [17] [18] [19] [20] , while in gastrinomas the diagnostic sensitivity of the test is nearly 100%.
On the other hand, the sensitivity drops in multifocal lesions and those located outside of the pancreas. Therefore, we might conclude that a negative EUS result virtually excludes the presence of a pancreatic tumour [9, 10] . EUS image of a pancreatic head NET.
FIGURE 2.
Vasculature assessment of a pancreatic head NET. ic NET patients, as early detection of pancreatic lesions enable radical treatment of the disease [9, 10] .
EUS DEVELOPMENT PROSPECTS
Endoscopic ultrasound is a continuously developing method, software. Throughout the follow-up period, the sensitivity of the method was estimated as 91.4%, and its specificity as 88.9%, which testifies to a high diagnostic accuracy of the test [28] .
SUMMARY
Endoscopic ultrasound is a highly sensitive and specific method in the imaging diagnostics of focal pancreatic lesions, including neuroendocrine tumours. Thanks to the possibility of acquiring images from the immediate vicinity of the pancreas, EUS is capable of detecting lesions as small as 1-2 mm in diameter. An additional advantage of the method is the possibility of performing biopsy, for further histopathological and cytological examination, which confirms the nature of the lesions, before planned surgical management. Therefore, alongside scintigraphy and hormonal assessment, endosonography is an essential diagnostic method in those rare digestive tract neoplasms.
